Laryngeal granuloma

Summary

Laryngeal granuloma (MONDO:0020974) is a disease and 1 clinical trial. Top therapeutic interventions include onabotulinumtoxina. A subtype of laryngeal disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	laryngeal granuloma
Mondo ID	MONDO:0020974
MeSH	D006102
SNOMED CT	72211003
UMLS	C0018196
MedGen	6674
Is cancer (heuristic)	no

Also known as: Granuloma of Larynx · Granuloma, Laryngeal · Granulomas, Laryngeal · laryngeal granuloma · Laryngeal Granulomas · Larynx Granuloma · Larynx Granulomas

Disease family

This is a subtype of laryngeal disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › upper respiratory tract disorder › laryngeal disorder › laryngeal granuloma

Related subtypes (19): spasmodic dystonia, laryngostenosis, laryngitis, laryngeal abductor paralysis, congenital laryngomalacia, larynx atresia, congenital laryngeal web, H syndrome, primary laryngeal lymphangioma, congenital laryngeal palsy, congenital subglottic stenosis, congenital laryngeal cyst, laryngocele, laryngeal diphtheria, laryngeal neoplasm, polyp of vocal cord, voice disorders, acquired laryngomalacia, idiopathic subglottic stenosis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01678053	PHASE2	WITHDRAWN	Efficacy Study of Botulinum Toxin (BOTOX) Injections to Treat Vocal Fold Granulomas

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ONABOTULINUMTOXINA	4	1